Cogent Biosciences, Inc.
No enriched coverage for $COGT in the last 7 days.
No SEC Form 4 filings for $COGT in the last 30 days.
Cogent Biosciences (NASDAQ:COGT) experienced a significant 30.9% drop in short interest in April, totaling 12,038,491 shares. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $43.45. Trading near $36.56, Cogent Biosciences has a market capitalization of $6.24 billion and recently reported a quarterly loss of ($0.55) EPS.
Cogent Biosciences' (COGT) shares are under scrutiny after new SUMMIT trial data for bezuclastinib in NonAdvanced Systemic Mastocytosis. Despite significant past returns, current trading at a 10.9x Price-to-Book ratio, much higher than the biotech industry average of 2.7x, suggests investors are placing high value on its pipeline. The company is unprofitable with growing losses, indicating that the market anticipates future success from its drug programs like bezuclastinib, but also highlighting risks of clinical setbacks and shareholder dilution.
Cogent Biosciences announced positive 48-week data from its SUMMIT trial for bezuclastinib in NonAdvanced systemic mastocytosis (NonAdvSM), showing a 56% improvement in Total Symptom Score and high rates of serum tryptase reduction and normalization. The results also indicated clinically meaningful improvements in bone mineral density, supporting bezuclastinib's potential as a disease-modifying agent. The company also reported inducement equity grants for new employees.
